NASDAQ:MXCT

MaxCyte (MXCT) Stock Forecast, Price & News

$3.02

-0.10 (-3.21%)

(As of 10/2/2023 ET)

Compare

Today's Range: $3.01
▼
$3.15
50-Day Range: $3.02
▼
$4.78
52-Week Range: $2.99
▼
$7.50

Volume: 385,497 shs
Average Volume: 495,171 shs
Market Capitalization: $312.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.50

MaxCyte MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 247.7% Upside
$10.50 Price Target
Short Interest: Bearish
2.30% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$120,981 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.37) to ($0.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

600th out of 969 stocks

Commercial Physical Research Industry

11th out of 14 stocks

3.5

Analyst's Opinion

Consensus Rating
MaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.50, MaxCyte has a forecasted upside of 247.7% from its current price of $3.02.
Amount of Analyst Coverage
MaxCyte has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.30% of the float of MaxCyte has been sold short.
Short Interest Ratio / Days to Cover
MaxCyte has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in MaxCyte has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
MaxCyte does not currently pay a dividend.
Dividend Growth
MaxCyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MXCT.

3.3

News and Social Media Coverage

News Sentiment
MaxCyte has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for MaxCyte this week, compared to 0 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $120,981.00 in company stock.
Percentage Held by Insiders
Only 6.00% of the stock of MaxCyte is held by insiders.
Percentage Held by Institutions
62.25% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MaxCyte are expected to decrease in the coming year, from ($0.37) to ($0.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MaxCyte is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MaxCyte is -9.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MaxCyte has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MaxCyte (NASDAQ:MXCT) Stock

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Price History

30 days | 90 days | 365 days | Advanced Chart

MXCT Stock News Headlines

September 6, 2023 | finanznachrichten.de

MaxCyte, Inc: MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

September 6, 2023 | finance.yahoo.com

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

October 2, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

September 5, 2023 | finance.yahoo.com

MaxCyte to Participate in Baird Global Healthcare Conference

August 11, 2023 | finanznachrichten.de

MaxCyte, Inc.: MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

July 10, 2023 | finanznachrichten.de

MaxCyte, Inc: MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

July 8, 2023 | finance.yahoo.com

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company

June 9, 2023 | seekingalpha.com

PRTS, CRBU and NDLS are among after hour movers

October 2, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

May 30, 2023 | msn.com

MaxCyte: Engineering The Next Biotech Wave

May 18, 2023 | finanznachrichten.de

MaxCyte, Inc: MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

May 12, 2023 | msn.com

Recap: MaxCyte Q1 Earnings

May 11, 2023 | seekingalpha.com

MaxCyte, Inc. 2023 Q1 - Results - Earnings Call Presentation

May 10, 2023 | finance.yahoo.com

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates

May 10, 2023 | finance.yahoo.com

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

May 4, 2023 | finance.yahoo.com

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

April 12, 2023 | finance.yahoo.com

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

April 6, 2023 | finance.yahoo.com

The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing

March 17, 2023 | finance.yahoo.com

MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021)

March 15, 2023 | msn.com

MaxCyte GAAP EPS of -$0.05 beats by $0.02, revenue of $10.88M misses by $2.25M

March 15, 2023 | finance.yahoo.com

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

February 1, 2023 | finance.yahoo.com

MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

January 3, 2023 | finance.yahoo.com

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

December 8, 2022 | finance.yahoo.com

MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade

December 6, 2022 | seekingalpha.com

MaxCyte Is Poised For A Strong Rebound

December 5, 2022 | markets.businessinsider.com

MaxCyte, Curamys In Strategic Platform License Deal

November 13, 2022 | fool.com

MaxCyte, Inc. (NASDAQ: MXCT)

See More Headlines

Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Company Calendar

Last Earnings: 8/09/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MXCT
CUSIP: N/A
CIK: 1287098
Web: maxcyte.com
Phone: 301-944-1700
Fax: 301-944-1703
Employees: 125
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.50
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +236.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,570,000.00
Net Margins: -80.22%
Pretax Margin: -80.22%
Return on Equity: -13.09%
Return on Assets: -11.60%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.92
Quick Ratio: 17.08

Sales & Book Value

Annual Sales: $44.26 million
Price / Sales: 7.30
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.47 per share
Price / Book: 1.26

Miscellaneous

Outstanding Shares: 103,540,000
Free Float: 97,325,000
Market Cap: $323.04 million
Optionable: Optionable
Beta: 0.84

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Douglas Arthur Doerfler (Age 67)
Founder, Pres, CEO & Exec. Director
Comp: $1.2M

Dr. Cenk Sumen Ph.D. (Age 49)
Chief Scientific Officer
Comp: $575.6k

Mr. Maher Masoud (Age 48)
Exec. VP, Gen. Counsel & Sec.
Comp: $612.07k

Mr. Douglas J. Swirsky CFA (Age 54)
CPA, Chief Financial Officer

Mr. Ronald Evan Holtz CPA (Age 65)
Ph.D., Exec. VP of Admin.

Mr. Sean Menarguez
Director of Investor Relations

Mr. Thomas Michael Ross (Age 62)
Exec. VP of Global Sales & Marketing

Dr. J. Stark Thompson Ph.D. (Age 81)
Consultant

Dr. James Brady Ph.D.
Sr. VP of Technical Applications & Customer Support

Dr. Sarah Haecker Meeks Ph.D.
Sr. VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MXCT Stock - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings or view top-rated stocks.
What is MaxCyte's stock price forecast for 2023?: 1 analysts have issued 1 year target prices for MaxCyte's stock. Their MXCT share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 236.5% from the stock's current price.
View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts.
How have MXCT shares performed in 2023?: MaxCyte's stock was trading at $5.46 at the beginning of 2023. Since then, MXCT shares have decreased by 42.9% and is now trading at $3.12.
View the best growth stocks for 2023 here.
When is MaxCyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our MXCT earnings forecast.
How were MaxCyte's earnings last quarter?: MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The firm earned $9.04 million during the quarter, compared to analyst estimates of $11 million. MaxCyte had a negative trailing twelve-month return on equity of 13.09% and a negative net margin of 80.22%.
When did MaxCyte IPO?: (MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share.

What is MaxCyte's stock symbol?: MaxCyte trades on the NASDAQ under the ticker symbol "MXCT."
How do I buy shares of MaxCyte?: Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MaxCyte's stock price today?: One share of MXCT stock can currently be purchased for approximately $3.12.
How much money does MaxCyte make?: MaxCyte (NASDAQ:MXCT) has a market capitalization of $323.04 million and generates $44.26 million in revenue each year. The company earns $-23,570,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.
How many employees does MaxCyte have?: The company employs 125 workers across the globe.
How can I contact MaxCyte?: MaxCyte's mailing address is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. The official website for the company is maxcyte.com. The company can be reached via phone at 301-944-1700, via email at ir@maxcyte.com, or via fax at 301-944-1703.

This page (NASDAQ:MXCT) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial